Trump Denies Reports of FDA Commissioner Makary’s Imminent Firing: ‘I Know Nothing About It’
President Donald Trump on Friday dismissed reports that he had signed off on a plan to fire Food and Drug Administration (FDA) Commissioner Dr. Marty Makary, telling reporters, “I’ve been reading about it, but I know nothing about it.” The denial comes amid growing speculation—fueled by The Wall Street Journal and CNN—that the White House is preparing to remove Makary over disputes involving drug approvals, including flavored nicotine vapes, and his handling of restrictions on the abortion pill mifepristone.
Background: Why Is Makary Under Fire?
Dr. Marty Makary, a surgeon and health policy expert, was confirmed as FDA Commissioner in March 2025 after a contentious nomination process. His tenure has been marked by controversies, including:
- Disputes over flavored nicotine vapes: According to The Wall Street Journal, Trump administration officials reportedly pressured Makary to fast-track approvals for flavored nicotine vapes, a move Makary resisted. The Journal cited sources claiming Trump’s frustration over the delay contributed to the push for Makary’s removal.
- Abortion pill restrictions: Anti-abortion activists and allies have criticized Makary for not taking stronger action to limit access to mifepristone, the abortion pill approved by the FDA in 2000. The controversy intensified after the Supreme Court’s Dobbs v. Jackson Women’s Health Organization decision in 2022, which overturned Roe v. Wade.
- Pharmaceutical industry complaints: Reports suggest that drug companies have also expressed dissatisfaction with Makary’s leadership, particularly regarding the pace of drug approvals and regulatory decisions.
While Trump did not confirm the reports, a senior administration official told CNN that he had indeed signed off on a plan to oust Makary, though the decision was not yet final. The official noted that Trump could still change his mind, given the political sensitivity of the issue.
Trump’s Response: ‘Fake News’ or Strategic Ambiguity?
When pressed by reporters outside the White House on Friday, Trump repeatedly downplayed the reports:
“I’ve been reading about it, but I know nothing about it.”
He also denied plans to appoint a new FDA commissioner, saying, “No, no.” The White House and the Department of Health and Human Services (HHS) did not respond to requests for comment from CNN or other outlets.
Trump’s refusal to address the matter directly has left room for speculation. Some analysts suggest the president may be testing public reaction before making a final decision, particularly with the midterm elections approaching in November. Others argue that the reports could be an attempt to pressure Makary into aligning more closely with the administration’s priorities.
Key Stakeholders React: Anti-Abortion Groups and Industry Pressure
Makary’s potential removal has drawn sharp reactions from multiple fronts:
- Anti-abortion activists: Groups like Susan B. Anthony Pro-Life America and March for Life have long criticized Makary for not moving aggressively enough to restrict mifepristone. Some allies have privately urged Trump to replace Makary with someone more sympathetic to their cause.
- Pharmaceutical industry: Executives from major drug companies have reportedly expressed frustration with the FDA’s approval processes under Makary, particularly for new treatments in oncology and rare diseases.
- Public health advocates: Organizations such as the American Medical Association (AMA) have defended Makary, arguing that his decisions—including on drug approvals—have been scientifically sound and aligned with public health goals.
If Makary is fired, it would create another leadership vacuum at HHS, which already faces challenges with staffing and policy coordination. The FDA’s role in regulating drugs, medical devices, and public health emergencies would also come under scrutiny, particularly in an election year.
What’s Next? Uncertainty Looms Over the FDA’s Future
The situation remains fluid. While Trump has not taken action, the following scenarios are possible:
- Makary remains in place: If Trump decides against firing Makary, the commissioner could continue his work, though political pressure may persist.
- Makary is replaced: Should Trump proceed with the removal, the process of nominating and confirming a successor could take months, leaving the FDA in a period of transition.
- Political fallout: Either outcome could have implications for Trump’s relationship with anti-abortion groups, public health advocates, and the pharmaceutical industry.
One thing is clear: The FDA’s future under Trump’s second term is now more uncertain than ever. With the midterms on the horizon, the decision could also serve as a litmus test for how the administration balances regulatory authority with political priorities.
FAQ: What You Need to Know About the FDA Commissioner Controversy
1. Who is Dr. Marty Makary?
Dr. Marty Makary is a surgeon and health policy expert who was confirmed as the 23rd FDA Commissioner in March 2025. Before his appointment, he served as a professor at Johns Hopkins University and was a vocal critic of certain aspects of the FDA’s drug approval process.
2. Why are anti-abortion groups targeting Makary?
Anti-abortion advocates argue that Makary has not done enough to restrict access to mifepristone, the abortion pill. They believe his leadership at the FDA has allowed the drug to remain widely available despite legal challenges and political pressure to limit its use.
3. What are flavored nicotine vapes, and why do they matter?
Flavored nicotine vapes are electronic cigarettes that come in flavors like mint, fruit, and candy. The FDA has faced criticism for both approving and delaying certain products. Trump administration officials reportedly wanted faster approvals for these products, which are popular among young users but banned in some states.
4. Could Makary’s firing hurt Trump politically?
It depends on the context. Anti-abortion groups might see it as a win, but public health advocates and some voters could view it as an overreach by the administration. The timing—with midterms approaching—adds another layer of political calculation.
5. What happens if Makary is fired?
If Trump removes Makary, the FDA would enter a period of uncertainty. The process of nominating and confirming a replacement could take months, during which the agency’s decision-making could be delayed or disrupted.
Key Takeaways
- Trump has denied reports of a plan to fire FDA Commissioner Dr. Marty Makary, saying he knows “nothing about it.”
- The controversy stems from disputes over drug approvals, including flavored nicotine vapes, and Makary’s handling of mifepristone restrictions.
- Anti-abortion groups, pharmaceutical companies, and public health advocates have all weighed in on the issue, creating a politically charged environment.
- If Makary is removed, the FDA could face leadership instability ahead of the midterm elections.
- The situation reflects broader tensions between regulatory authority and political priorities in the Trump administration.